ArticleClinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association2026
Differential Effects of Cardiometabolic Risk Factors on All-Cause Mortality in United States Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).
Article in Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Clinical outcomes of lean metabolic dysfunction-associated steatotic liver disease by phenotypic subtypes.Journal of gastroenterology · 2026Article
- Interpreting risk across lean MASLD phenotypes.Journal of gastroenterology · 2026Article
- Joint effects of social determinants of health on NAFLD mortality: the mediating role of phenotypic age acceleration.GeroScience · 2026Article
- Prediction of trajectories and outcomes in early-stage metabolic dysfunction-associated steatotic liver disease: a narrative review.EClinicalMedicine · 2026Review
- Dapagliflozin in Metabolic Dysfunction-Associated Steatotic Liver Disease: Clinical Evidence and Therapeutic Potential.Euroasian journal of hepato-gastroenterologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
BACKGROUND &
aimsMetabolic dysfunction-associated steatotic liver disease (MASLD) is defined by abnormalities in cardiometabolic risk factors (CMRFs). Characterizing the contribution of individual CMRFs to clinical outcomes may guide prioritization of interventions. We evaluated the association of individual CMRFs with all-cause mortality in United States adults with MASLD.
methodsParticipants in the National Health and Nutrition Examination Survey (NHANES) III (1988-1994) and continuous NHANES (1999-2018) were linked to mortality data through 2019. Adults >20 years of age were included if their Fatty Liver Index (FLI) was >60 and they had at least one CMRF (overweight/obesity, glucose intolerance, high blood pressure, triglycerides, or low high-density lipoprotein [HDL]). Cox regression analyzed risk of all-cause mortality adjusted for age, sex, and Fibrosis-4 (FIB-4).
resultsAmong 21,872 participants included (mean age, 50 years; 53% male), the mean body mass index (BMI) was 33.6 kg/m
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.